Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration

Katerina Chatzidionysiou; Elisabeth Lie; Evgeny Nasonov; Galina Lukina; Merete Lund Hetland; Ulrik Tarp; Ioan Ancuta; Karel Pavelka; Dan C Nordström; Cem Gabay; Helene Canhão; Matija Tomsic; Piet L C M van Riel; Juan Gomez-Reino; Tore K. Kvien; Ronald F van Vollenhoven

doi:10.1186/s13075-016-0951-z

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration

Katerina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, Galina Lukina, Merete Lund Hetland, Ulrik Tarp, Ioan Ancuta, Karel Pavelka, Dan C Nordström, Cem Gabay, Helene Canhão, Matija Tomsic, Piet L C M van Riel, Juan Gomez-Reino, Tore K. Kvien, Ronald F van Vollenhoven

Institut for Klinisk Medicin

32 Citationer (Scopus)

Abstract

Background: The approved dose of rituximab (RTX) in rheumatoid arthritis is 1000 mg × 2, but some data have suggested similar clinical efficacy with 500 mg × 2. The purpose of this study was to compare the effectiveness of the regular and low doses given as first treatment course. Methods: Twelve European registries participating in the CERERRA collaboration (The European Collaborative Registries for the Evaluation of Rituximab in Rheumatoid Arthritis) submitted anonymized datasets with demographic, efficacy and treatment data for patients who had started RTX. Treatment effectiveness was assessed by DAS28 reductions and EULAR responses after 6 months. Results: Data on RTX dose were available for 2,873 patients, of whom 2,625 (91.4 %) and 248 (8.6 %) received 1000 mg × 2 and 500 mg × 2, respectively. Patients treated with 500 mg × 2 were significantly older, had longer disease duration, higher number of prior DMARDs, but lower number of prior biologics and lower baseline DAS28 than those treated with 1000 mg × 2. Fewer patients in the low-dose group received concomitant DMARDs but more frequently received concomitant corticosteroids. Both doses led to significant clinical improvements at 6 months. DAS28 reductions at 6 months were comparable in the 2 dose regimens [mean DeltaDAS28 ± SD -2.0 ± 1.3 (high dose) vs. -1.7 ± 1.4 (low dose), p = 0.23 adjusted for baseline differences]. Similar percentages of patients achieved EULAR good response in the two dose groups, 18.4 % vs. 17.3 %, respectively (p = 0.36). Conclusions: In this large observational cohort initial treatment with RTX at 500 mg × 2 and 1000 mg × 2 led to comparable clinical outcomes at 6 months.

Originalsprog	Engelsk
Artikelnummer	50
Tidsskrift	Arthritis Research & Therapy
Vol/bind	18
Udgave nummer	1
Sider (fra-til)	1-6
Antal sider	6
ISSN	1478-6362
DOI	https://doi.org/10.1186/s13075-016-0951-z https://doi.org/10.1186/s13075-016-1048-4
Status	Udgivet - 16 feb. 2016

Adgang til dokumentet

10.1186/s13075-016-0951-zLicens: CC BY
10.1186/s13075-016-1048-4Licens: CC BY

Citationsformater

Chatzidionysiou, K., Lie, E., Nasonov, E., Lukina, G., Hetland, M. L., Tarp, U., Ancuta, I., Pavelka, K., Nordström, D. C., Gabay, C., Canhão, H., Tomsic, M., van Riel, P. L. C. M., Gomez-Reino, J., Kvien, T. K., & van Vollenhoven, R. F. (2016). Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Research & Therapy, 18(1), 1-6. [50]. https://doi.org/10.1186/s13075-016-0951-z, https://doi.org/10.1186/s13075-016-1048-4

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort : data from the CERERRA collaboration. / Chatzidionysiou, Katerina; Lie, Elisabeth; Nasonov, Evgeny et al.

I: Arthritis Research & Therapy, Bind 18, Nr. 1, 50, 16.02.2016, s. 1-6.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Chatzidionysiou, K, Lie, E, Nasonov, E, Lukina, G, Hetland, ML, Tarp, U, Ancuta, I, Pavelka, K, Nordström, DC, Gabay, C, Canhão, H, Tomsic, M, van Riel, PLCM, Gomez-Reino, J, Kvien, TK & van Vollenhoven, RF 2016, 'Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration', Arthritis Research & Therapy, bind 18, nr. 1, 50, s. 1-6. https://doi.org/10.1186/s13075-016-0951-z, https://doi.org/10.1186/s13075-016-1048-4

@article{20c419ee520c488593b8f46779cd1130,

title = "Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration",

abstract = "Background: The approved dose of rituximab (RTX) in rheumatoid arthritis is 1000 mg × 2, but some data have suggested similar clinical efficacy with 500 mg × 2. The purpose of this study was to compare the effectiveness of the regular and low doses given as first treatment course. Methods: Twelve European registries participating in the CERERRA collaboration (The European Collaborative Registries for the Evaluation of Rituximab in Rheumatoid Arthritis) submitted anonymized datasets with demographic, efficacy and treatment data for patients who had started RTX. Treatment effectiveness was assessed by DAS28 reductions and EULAR responses after 6 months. Results: Data on RTX dose were available for 2,873 patients, of whom 2,625 (91.4 %) and 248 (8.6 %) received 1000 mg × 2 and 500 mg × 2, respectively. Patients treated with 500 mg × 2 were significantly older, had longer disease duration, higher number of prior DMARDs, but lower number of prior biologics and lower baseline DAS28 than those treated with 1000 mg × 2. Fewer patients in the low-dose group received concomitant DMARDs but more frequently received concomitant corticosteroids. Both doses led to significant clinical improvements at 6 months. DAS28 reductions at 6 months were comparable in the 2 dose regimens [mean DeltaDAS28 ± SD -2.0 ± 1.3 (high dose) vs. -1.7 ± 1.4 (low dose), p = 0.23 adjusted for baseline differences]. Similar percentages of patients achieved EULAR good response in the two dose groups, 18.4 % vs. 17.3 %, respectively (p = 0.36). Conclusions: In this large observational cohort initial treatment with RTX at 500 mg × 2 and 1000 mg × 2 led to comparable clinical outcomes at 6 months.",

author = "Katerina Chatzidionysiou and Elisabeth Lie and Evgeny Nasonov and Galina Lukina and Hetland, {Merete Lund} and Ulrik Tarp and Ioan Ancuta and Karel Pavelka and Nordstr{\"o}m, {Dan C} and Cem Gabay and Helene Canh{\~a}o and Matija Tomsic and {van Riel}, {Piet L C M} and Juan Gomez-Reino and Kvien, {Tore K.} and {van Vollenhoven}, {Ronald F}",

year = "2016",

month = feb,

day = "16",

doi = "10.1186/s13075-016-0951-z",

language = "English",

volume = "18",

pages = "1--6",

journal = "Arthritis Research & Therapy",

issn = "1478-6354",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort

T2 - data from the CERERRA collaboration

AU - Chatzidionysiou, Katerina

AU - Lie, Elisabeth

AU - Nasonov, Evgeny

AU - Lukina, Galina

AU - Hetland, Merete Lund

AU - Tarp, Ulrik

AU - Ancuta, Ioan

AU - Pavelka, Karel

AU - Nordström, Dan C

AU - Gabay, Cem

AU - Canhão, Helene

AU - Tomsic, Matija

AU - van Riel, Piet L C M

AU - Gomez-Reino, Juan

AU - Kvien, Tore K.

AU - van Vollenhoven, Ronald F

PY - 2016/2/16

Y1 - 2016/2/16

N2 - Background: The approved dose of rituximab (RTX) in rheumatoid arthritis is 1000 mg × 2, but some data have suggested similar clinical efficacy with 500 mg × 2. The purpose of this study was to compare the effectiveness of the regular and low doses given as first treatment course. Methods: Twelve European registries participating in the CERERRA collaboration (The European Collaborative Registries for the Evaluation of Rituximab in Rheumatoid Arthritis) submitted anonymized datasets with demographic, efficacy and treatment data for patients who had started RTX. Treatment effectiveness was assessed by DAS28 reductions and EULAR responses after 6 months. Results: Data on RTX dose were available for 2,873 patients, of whom 2,625 (91.4 %) and 248 (8.6 %) received 1000 mg × 2 and 500 mg × 2, respectively. Patients treated with 500 mg × 2 were significantly older, had longer disease duration, higher number of prior DMARDs, but lower number of prior biologics and lower baseline DAS28 than those treated with 1000 mg × 2. Fewer patients in the low-dose group received concomitant DMARDs but more frequently received concomitant corticosteroids. Both doses led to significant clinical improvements at 6 months. DAS28 reductions at 6 months were comparable in the 2 dose regimens [mean DeltaDAS28 ± SD -2.0 ± 1.3 (high dose) vs. -1.7 ± 1.4 (low dose), p = 0.23 adjusted for baseline differences]. Similar percentages of patients achieved EULAR good response in the two dose groups, 18.4 % vs. 17.3 %, respectively (p = 0.36). Conclusions: In this large observational cohort initial treatment with RTX at 500 mg × 2 and 1000 mg × 2 led to comparable clinical outcomes at 6 months.

AB - Background: The approved dose of rituximab (RTX) in rheumatoid arthritis is 1000 mg × 2, but some data have suggested similar clinical efficacy with 500 mg × 2. The purpose of this study was to compare the effectiveness of the regular and low doses given as first treatment course. Methods: Twelve European registries participating in the CERERRA collaboration (The European Collaborative Registries for the Evaluation of Rituximab in Rheumatoid Arthritis) submitted anonymized datasets with demographic, efficacy and treatment data for patients who had started RTX. Treatment effectiveness was assessed by DAS28 reductions and EULAR responses after 6 months. Results: Data on RTX dose were available for 2,873 patients, of whom 2,625 (91.4 %) and 248 (8.6 %) received 1000 mg × 2 and 500 mg × 2, respectively. Patients treated with 500 mg × 2 were significantly older, had longer disease duration, higher number of prior DMARDs, but lower number of prior biologics and lower baseline DAS28 than those treated with 1000 mg × 2. Fewer patients in the low-dose group received concomitant DMARDs but more frequently received concomitant corticosteroids. Both doses led to significant clinical improvements at 6 months. DAS28 reductions at 6 months were comparable in the 2 dose regimens [mean DeltaDAS28 ± SD -2.0 ± 1.3 (high dose) vs. -1.7 ± 1.4 (low dose), p = 0.23 adjusted for baseline differences]. Similar percentages of patients achieved EULAR good response in the two dose groups, 18.4 % vs. 17.3 %, respectively (p = 0.36). Conclusions: In this large observational cohort initial treatment with RTX at 500 mg × 2 and 1000 mg × 2 led to comparable clinical outcomes at 6 months.

U2 - 10.1186/s13075-016-0951-z

DO - 10.1186/s13075-016-0951-z

M3 - Journal article

SN - 1478-6354

VL - 18

SP - 1

EP - 6

JO - Arthritis Research & Therapy

JF - Arthritis Research & Therapy

IS - 1

M1 - 50

ER -

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater